Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1717-1723

  Wolff, Inge ^a   Bench, Karin ^a   Beijnen, Jos H ^b   Bruntsch, Utta ^a   Cavalli, Franco ^d   De Jong, Jolanda ^d   Groot, Yvonne ^c   Van Tellingen, Olaf ^b   Wanders, Jantien ^c   Sessa, Cristiana ^d  

^a 5 Medical Department   (Germany)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c New Drug Development Office 1081 HV   (Netherlands)

^d OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARZELESIN;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULTRAVIOLET SPECTROPHOTOMETRY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZOFURANS; BRONCHIAL SPASM; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUSHING; HUMANS; HYPERSENSITIVITY; INDOLES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 10244249179     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Reynolds, V. L., McGovren, J. P., and Hurley, L. The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumour antibiotic. J. Antibiot. (Tokyo), 39: 319-334, 1986.
2. Swenson, D. H., Li, L. H., Hurley, L. H., Rokem, J. S., Petzold, G. L., Dayton, B. D., Wallace, T. L., Lin, A. H., and Krueger, W. C. Mechanism of interaction of CC 1065 (NSC 298 223) with DNA. Cancer Res., 42: 2821-2828, 1982.
3. Shamdas, G. J., Alberts, D. S., Modiano, M., Wiggins, C , Power, J., Kasunic, D. A., Elfring, G. L., and Earhart, R. H. Phase I study of adozelesin (U-73975) in patients with solid tumours. Anticancer Drugs, 5: 10-14, 1994.
4. Fleming, G. F., Ratain, M. J., O'Brien, S. M., Schilsky, R. L., Hoffman, P. C., Richards, J. M., Vogelzang, N. J., Kasunic, D. A., and Earhart, R. H. Phase I study of adozelesin administered by 24 h continuous intravenous infusion. J. Natl. Cancer. Inst. USA, 86: 368-372, 1994.
5. Li, L. H., DeKoning, T. F , Kelly, R. C., Krueger, W. C., McGovren, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D., and Gebhard, I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res., 52: 4904-4913, 1992.
6. Houghton, P. J., Cheshire, P. J., Hallman, J. D., and Houghton, J. A. Therapeutic efficacy of the cyclopropylpyrroloindolc, carzelesin, against xenografts derived from adult and childhood solid tumours. Cancer Chemother. Pharmacol., 36: 45-52, 1995.
7. Toxicology Studies of Carzelesin (U-80244). EORTC NDDO Report. EORTC NDDO, 1992.
8. Jonkman-de Vries, J. D., de Graaff-Teulen, J. A., Henrar, R. E. C., Kettenes-van den Bosch, J., Bult, A., and Beijnen, J. H. Pharmaceutical development of a patenteral formulation of the novel antitumour agent carzelesin (U-80244). Invest. New Drugs, 12: 303-314, 1994.
9. Van Tellingen, O., Pels, E. M., Henrar, R. E. C., Schaaf, L. J., Padbury, G. E., Beijnen, J. H., and Nooijnen, W. J. Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80244) and metabolites (U-76073 and U-76074) in human plasma. J. Chromatogr., 652: 51-58, 1994.
10. D'Incalci, M. DNA-minor-groove alkylators, a new class of anti-cancer agents. Ann. Oncol., 5: 877-878, 1994.
11. Pezzoni, G., Grandi, M., Biasoli, G., Capolongo, L., Ballinari, D., Giuliani, F. C., Barbieri, B., Pastori, A., Pesenti, E., and Mongelli, N. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br. J. Cancer, 64: 1047-1050, 1991.
12. Van Tellingen, O., Beijnen, J. H., Nooijen, W. J., van Oene, S., Henrar, R. E. C., Schaaf, L. J., and Padbury, G. E. Plasma pharmacokinetics of carzelesin (U-80244) and metabolites (U-76073, U-76074) in mice and rats Ann. Oncol., 5 (Suppl. 5): 171, 1994.
13. Awada, A., Punt, C J. A., Gil, T., Kwakkelstein, M. O., Van Tellingen, O., Wagener, D. J. T., and Piccart, M. J. Phase 1 clinical and pharmacokinetic study of carzelesin (U80 244) administered on a 4-weekly i.v. bolus schedule. Proc. Am. Assoc. Cancer Res., 36: 237, 1995
14. Sessa, C., Pagani, O., Zurlo, M. G., de Jong, J., Hofman, C., Lassus, M., Marrari, P., Strolin Benedetti, M., and Cavalh, F. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann. Oncol., 5: 901-907, 1994.
15. Ghielmini, M., Bosshard, G., Soldati, G., D'Incalci, M., Sessa, C., and Cavalli, F. The myelotoxicity of new anticancer agents (distamycin derivatives) can be estimated by clonogenic assay on human umbilical cord blood cells. Schweiz. Med. Wochenschr., 125 (Suppl. 69): 135, 1995.